tert-Butyl 4-(4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate

Catalog No. :
ACLOQX932
CAS No. :
158985-36-5
Molecular Formula :
C17H24N2O4
Molecular Weight :
320.39

IUPAC Name:tert-butyl 4-(4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate

tert-Butyl 4-(4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$187.00Login to see priceIn stockInquiry
25g97%$747.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
MDL No.MFCD06200865
Molecular FormulaC17H24N2O4
Molecular Weight320.39
SMILESCOC(=O)C1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C
InChI KeySMDBCJAJWDCJOP-UHFFFAOYSA-N
SynonymAC-14208 | 1-(tert-Butoxycarbonyl)-4-(4-methoxycarbonylphenyl)piperazine | Methyl 4-(N-Boc-N'-piperazinyl)benzoate | Methyl 4-[1-(tert-butoxycarbonyl)piperazin-4-yl]benzoate | FT-0654120 | SCHEMBL2388387 | 1-(tert-butoxycarbonyl) -4-(4-methoxycarbonylphen
CAS No.158985-36-5

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H300-H319
Precautionary Statement(s)
P264-P301+P310-P305+P351+P338

Synthetic Route by SureRoute

1. ACLOQX932 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACNRGL042 route compound structure diagram
    ACNRGL042403-33-8 In Stock
  4. Then
  5. ACLOQX932 route product structure diagram
    ACLOQX932158985-36-5 In Stock
Inquiry

2. ACLOQX932 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDSAM359 route compound structure diagram
    ACDSAM359619-42-1 In Stock
  2. Then
  3. ACLOQX932 route product structure diagram
    ACLOQX932158985-36-5 In Stock
Inquiry

Comments (0)